Company news

Cabaletta Bio, Inc. news in 2025

Cabaletta Bio, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

November 10, 2025

Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December

November 4, 2025

Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025

October 27, 2025

Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant

October 14, 2025

Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress

October 9, 2025

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

August 27, 2025

Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

August 7, 2025

Cabaletta Bio Announces Pricing of Public Offering of Securities

June 11, 2025

Cabaletta Bio Announces Proposed Public Offering of Securities

June 11, 2025

Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress

June 11, 2025

Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference

May 29, 2025

Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts

May 15, 2025

Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

March 31, 2025

Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform

March 18, 2025

Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference

February 26, 2025

UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

February 18, 2025

Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

February 18, 2025

Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February

February 10, 2025

Cabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech Conference

January 28, 2025

Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025

January 12, 2025

Decks in 2025